Targeted Radiation and Immune Therapies-Advances and Opportunities for the Treatment of Prostate Cancer.

Pharmaceutics · 2023 · PMC9863141 · PMID 36678880

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

did not reach statistical significancep = 0.053so close (0.05 < p ≤ 0.1)

Although this study trended towards improvement in the combination arm, it did not reach statistical significance with a median OS 11.2 vs. 10.0 months (HR = 0.85; p = 0.053) [ 72 ]. 8.2.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.